Poikonen et al. [72] have observed that Cyclin A2 protein overexpression is a better marker for poor prognosis (risk ratio, first relapse time, survival) than Ki-67, histological grade, or mitotic count in breast cancer patients. This evidence concerns the gene CCNA2 and breast carcinoma.